<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">77433</article-id><article-id pub-id-type="doi">10.7554/eLife.77433</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Evolutionary Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Comprehensive fitness landscape of SARS-CoV-2 M<sup>pro</sup> reveals insights into viral resistance mechanisms</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-166159"><name><surname>Flynn</surname><given-names>Julia M</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5490-393X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-269953"><name><surname>Samant</surname><given-names>Neha</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-269966"><name><surname>Schneider-Nachum</surname><given-names>Gily</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-269967"><name><surname>Bakan</surname><given-names>David T</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-269968"><name><surname>Yilmaz</surname><given-names>Nese Kurt</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-20602"><name><surname>Schiffer</surname><given-names>Celia A</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2270-6613</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-269969"><name><surname>Moquin</surname><given-names>Stephanie A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-269970"><name><surname>Dovala</surname><given-names>Dustin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" corresp="yes" id="author-12696"><name><surname>Bolon</surname><given-names>Daniel NA</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5857-6676</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Biochemistry and Molecular Pharmacology</institution>, <institution>University of Massachusetts Medical School</institution>, <addr-line><named-content content-type="city">Worcester</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution>Novartis</institution>, <addr-line><named-content content-type="city">Emeryville</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-123289"><name><surname>Ogbunugafor</surname><given-names>C Brandon</given-names></name><role>Reviewing editor</role><aff><institution>Yale University</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>Julia.Flynn@umassmed.edu</email> (JF);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>Dan.Bolon@umassmed.edu</email> (DB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>06</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e77433</elocation-id><history><date date-type="received"><day>28</day><month>01</month><year>2022</year></date><date date-type="accepted"><day>17</day><month>06</month><year>2022</year></date></history><permissions><copyright-statement>Â© 2022, Flynn et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Flynn et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-77433-v1.pdf"/><abstract><p>With the continual evolution of new strains of SARS-CoV-2 that are more virulent, transmissible, and able to evade current vaccines, there is an urgent need for effective anti-viral drugs SARS-CoV-2 main protease (M<sup>pro</sup>) is a leading target for drug design due to its conserved and indispensable role in the viral life cycle. Drugs targeting M<sup>pro</sup> appear promising but will elicit selection pressure for resistance. To understand resistance potential in M<sup>pro</sup>, we performed a comprehensive mutational scan of the protease that analyzed the function of all possible single amino acid changes. We developed three separate high-throughput assays of M<sup>pro</sup> function in yeast, based on either the ability of M<sup>pro</sup> variants to cleave at a defined cut-site or on the toxicity of their expression to yeast. We used deep sequencing to quantify the functional effects of each variant in each screen. The protein fitness landscapes from all three screens were strongly correlated, indicating that they captured the biophysical properties critical to M<sup>pro</sup> function. The fitness landscapes revealed a non-active site location on the surface that is extremely sensitive to mutation making it a favorable location to target with inhibitors. In addition, we found a network of critical amino acids that physically bridge the two active sites of the M<sup>pro</sup> dimer. The clinical variants of M<sup>pro</sup> were predominantly functional in our screens, indicating that M<sup>pro</sup> is under strong selection pressure in the human population. Our results provide predictions of mutations that will be readily accessible to M<sup>pro</sup> evolution and that are likely to contribute to drug resistance. This complete mutational guide of M<sup>pro</sup> can be used in the design of inhibitors with reduced potential of evolving viral resistance.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>S. cerevisiae</italic></kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100015311</institution-id><institution>Novartis Institutes for BioMedical Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Flynn</surname><given-names>Julia M</given-names></name><name><surname>Samant</surname><given-names>Neha</given-names></name><name><surname>Schneider-Nachum</surname><given-names>Gily</given-names></name><name><surname>Yilmaz</surname><given-names>Nese Kurt</given-names></name><name><surname>Schiffer</surname><given-names>Celia A</given-names></name><name><surname>Bolon</surname><given-names>Daniel NA</given-names></name></principal-award-recipient></award-group><funding-statement>DTB, SAM, and DD are employees of Novartis Institutes for Biomedical Research and were involved in study design, data interpretation, and preparation of this manuscript.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>David T Bakan, is an employee of Novartis..</p></fn><fn fn-type="conflict" id="conf3"><p>Stephanie A Moquin, is an employee of Novartis..</p></fn><fn fn-type="conflict" id="conf4"><p>Dustin Dovala, is an employee of Novartis..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Next generation sequencing data has been deposited to the NCBI short read archive (PRJNA842255).  Tabulated raw counts of all variants in all replicates are included in Figure 2 - source data 1. Figure 2 - source data 1, Figure 4 - source data 1, Figure 4 - source data 2, and Figure 5 - source data 1 contain the data used to generate all the figures.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Flynn JM</collab><collab>Bolon DNA</collab></person-group><year iso-8601-date="2022">2022</year><source>Comprehensive fitness landscape of SARS-CoV-2 Mpro in S. cerevisiae - raw sequence reads</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA842255">https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA842255</ext-link><comment>NCBI Short Read Archive, PRJNA842255</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-77433-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>